In a significant move towards bolstering its oncology portfolio, Merck KGaA has entered into an exclusive license agreement with Abbisko Therapeutics for pimicotinib (ABSK021), a potent small molecule CSF-1R inhibitor currently in Phase III clinical trials for the treatment of tenosynovial giant cell tumour (TGCT). The agreement, which could be worth up to US$605.5 M, provides an opportunity for Merck to address a significant unmet medical need and to expand its commercial footprint in oncology in China.